Ask Google

Results for traskrizzjonijiet translation from Maltese to English

Human contributions

From professional translators, enterprises, web pages and freely available translation repositories.

Add a translation

Maltese

English

Info

Maltese

Traskrizzjonijiet tal-ortografija Bjelorussa

English

Transcription of Belarusian spelling

Last Update: 2014-11-21
Usage Frequency: 2
Quality:

Maltese

(b) reġistrazzjonijiet u traskrizzjonijiet tar-reġistrazzjonijiet mill-unitajiet tal-kontroll tat-traffiku tal-ajru;

English

(ff) recordings and transcriptions of recordings from air traffic control units;

Last Update: 2017-04-06
Usage Frequency: 1
Quality:

Maltese

Ir-risponsi molekulari ta’ ≤0.01% u ≤0.0032% b’IS korrispondenti għal riduzzjoni log ≥4 u għal riduzzjoni log ≥4.5, rispettivament, tat- traskrizzjonijiet BCR-ABL minn linja bażi standardizzata.

English

Molecular responses of ≤0.01% and ≤0.0032% by IS correspond to a ≥4 log reduction and ≥4.5 log reduction, respectively, of BCR-ABL transcripts from a standardised baseline.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Maltese

Total ta’ 305 (36.1%) tal-pazjenti kollha ma setgħux ikunu evalwati għal MMR fit-48 xahar (98 fil-grupp mogħti 300 mg nilotinib darbtejn kuljum, 88 fil-grupp mogħti 400 mg imatinib darbtejn kuljum u 119 fil-grupp mogħti imatinib) minħabba nuqqas ta’ evalwazzjonijiet tal-PCR (n=18), traskrizzjonijiet atipiċi fil-linja bażi (n=8), jew twaqqif qabel il-perjodu ta’ 48 xahar (n=279).

English

A total of 305 (36.1%) of all patients were not evaluable for MMR at 48 months (98 in the nilotinib 300 mg BID group, 88 in the nilotinib 400 mg BID group and 119 in the imatinib group) due to missing/unevaluable PCR assessments (n=18), atypical transcripts at baseline (n=8), or discontinuation prior to the 48-month time point (n=279).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Maltese

Total ta’ 305 (36.1%) tal-pazjenti kollha ma setgħux ikunu evalwati għal MMR fit-48 xahar (98 fil-grupp mogħti 300 mg nilotinib darbtejn kuljum, 88 fil-grupp mogħti 400 mg imatinib darbtejn kuljum u 119 fil-grupp mogħti imatinib) minħabba nuqqas ta’ evalwazzjonijiet tal-PCR (n=18), traskrizzjonijiet atipiċi fil-linja bażi (n=8), jew twaqqif qabel il-perjodu ta’ 48 xahar (n=279).

English

A total of 305 (36.1%) of all patients were not evaluable for MMR at 48 months (98 in the nilotinib 300 mg twice daily group, 88 in the nilotinib 400 mg twice daily group and 119 in the imatinib group) due to missing/unevaluable PCR assessments (n=18), atypical transcripts at baseline (n=8), or discontinuation prior to the 48-month time point (n=279).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Maltese

Total ta’ 395 (46.7%) mill-pazjenti kollha ma setgħux jiġu evalwati għal MMR fit-72 xahar (130 fil-grupp ta’ nilotinib 300 mg darbtejn kuljum, 110 fil-grupp ta’ nilotinib 400 mg darbtejn kuljum u 155 fil-grupp ta’ imatinib) minħabba valutazzjonijiet ta’ PCR nieqsa/li ma jistgħux jiġu evalwati (n=25), traskrizzjonijiet atipiċi fil-linja bażi (n=8) jew twaqqif qabel il-perjodu ta’ 72 xahar (n=362).

English

A total of 395 (46.7%) of all patients were not evaluable for MMR at 72 months (130 in the nilotinib 300 mg twice daily group, 110 in the nilotinib 400 mg twice daily group and 155 in the imatinib group) due to missing/unevaluable PCR assessments (n=25), atypical transcripts at baseline (n=8) or discontinuation prior to the 72-month time point (n=362).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Maltese

Imfisser bħala proporzjon ta’ ≤ 0.1% ta’ BCR-ABL għal traskrizzjonijiet t’ABL fuq l-Iskala Internazzjonali (IS) (ie, ≤ 0.1% BCR-ABL IS; il-pazjenti għandhom jkollhom l-b2a2/b3a2 (traskrizzjoni ta’ (p210)), fid-demm periferali mkejjel bil-quantitative reverse transcriptase polymerase chain reaction (qRT PCR).

English

Defined as a ≤0.1% ratio of BCR-ABL to ABL transcripts on the International Scale (IS) (ie, ≤0.1% BCR-ABLIS; patients must have the b2a2/b3a2 (p210) transcript), in peripheral blood measured by quantitative reverse transcriptase polymerase chain reaction (qRT PCR).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Maltese

Total ta’ 322 (38.1%) tal-pazjenti kollha ma setgħux ikunu evalwati għal MMR fis-60 xahar (99 fil-grupp mogħti 300 mg nilotinib darbtejn kuljum, 93 fil-grupp mogħti 400 mg imatinib darbtejn kuljum u 130 fil-grupp mogħti imatinib) minħabba nuqqas ta’ evalwazzjonijiet tal-PCR (n=9), traskrizzjonijiet atipiċi fil-linja bażi (n=8), jew twaqqif qabel il-perjodu ta’ 60 xahar (n=305).

English

A total of 322 (38.1%) of all patients were not evaluable for MMR at 60 months (99 in the nilotinib 300 mg twice daily group, 93 in the nilotinib 400 mg twice daily group and 130 in the imatinib group) due to missing/unevaluable PCR assessments (n=9), atypical transcripts at baseline (n=8) or discontinuation prior to the 60-month time point (n=305).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Maltese

Bl-eċċezzjoni ta' meta hemm il-kunsens tal-membri tal-ekwipaġġ konċernati, il-vuċi tal-kabina tal-pilota u r-reġistrazzjonijiet tal-immaġini u t-traskrizzjonijiet tagħhom ma għandhomx jkunu disponibbli jew użati għal skopijiet għajr għall-investigazzjoni tas-sikurezza.

English

Except with the consent of all crew members concerned, cockpit voice and image recordings and their transcripts shall not be made available or used for purposes other than safety investigation.

Last Update: 2017-04-06
Usage Frequency: 1
Quality:

Get a better translation with
4,401,923,520 human contributions

Users are now asking for help:



We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. Learn more. OK